Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects

Authors: Y Cui, Y Huo, X Li, G Yang, Z Huang, X Zhao, L Qi, H Deng, S Zheng, P An, X Sun, H Li, X Wu, L Qian

Published: 2020-11-26

DOI: 10.1093/ehjci/ehaa946.3327

Source: Full article